Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02460224
Title Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

kidney cancer

colorectal cancer

melanoma

lung non-small cell carcinoma

Advanced Solid Tumor

stomach cancer

gastroesophageal junction adenocarcinoma

esophagus adenocarcinoma

nasopharynx carcinoma

Therapies

LAG525

Spartalizumab

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.